Recent Updates
Recently added Catalysts

HS-20110

Phase 1

Solid Tumors | Small molecule | Other |Roche Holding AG|Trials Updated: Apr 20, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment475

FDA Designations

No designations recorded

HS-20110 clinical trials

HS-20110 · 1 trial · 1 indication

Phase 1 1
NCT06892379A Study of HS-20110 in Participants With Advanced Solid TumorsSolid Tumors
RECRUITING475 Analytics
PHASE1RECRUITING
A Study of HS-20110 in Participants With Advanced Solid Tumors
Solid Tumors
NCT06892379475
Unlock trial analytics

Study Endpoints

Primary Endpoints

Maximum tolerated dose (MTD) or maximum applicable dose (MAD)
From day 1 to one months after the last dose in Phase 1a
Objective response rate (ORR) as per RECIST v1.1
From screening to 2 months after the last dose

Secondary Endpoints

Incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to dose modification or permanent discontinuation, and specific laboratory abnormalities
From the first dose until 90 days after the last dose
Objective response rate (ORR), disease control rate (DCR), duration of response (DoR), and progression-free survival (PFS) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; overall survival (OS)
From screening to up to 3 years after last dose
Incidence of anti-HS-20110 antibody (ADA)
From the first dose until 90 days after the last dose
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
HS-20110 (Phase Ia：Dose escalation )EXPERIMENTAL -
HS-20110 (Phase 1b Dose expansion)EXPERIMENTAL -

Interventions

NameTypeDescription
HS-20110 (Phase Ia：Dose escalation )DRUGHS-20110 for IV infusion of various dose strengths administered in 21 day dosing cycles
HS-20110 (Phase Ib:Dose expansion )DRUGThe recommended dose from the dose-escalation stage and other potential doses will be further explored
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites8

Inclusion Criteria: 1. Males or females, aged ≥ 18 years. 2. Participants with pathologically (histologically or cytologically) confirmed advanced solid tumors. 3. Participants have at least 1 target lesion other than CNS lesions according to RECIST 1.1. Exclusion Criteria: 1. Participants have r...

Countries:United StatesChina
Unlock Eligibility Criteria

Competitive Landscape -Other Solid Tumors 10 trials (matched to "Solid Tumors")

CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK3PHASE2Pembrolizumab, Gardasil 9
Incyte CorporationINCY1PHASE2Retifanlimab
Novartis AG Sponsored ADRNVS1PHASE1KFA115
Iovance Biotherapeutics IncIOVA2PHASE2Aldesleukin
AstraZeneca PLCAZN1 - Trastuzumab deruxtecan
Unlock Competitive Intelligence

Explore more on BiopharmaWatch

Roche Holding AG (RHHBY)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with HCompanies A to ZEvery biotech and pharma company we track